anti programmed cell death protein 1 pd 1  (Bio X Cell)

Journal: Journal for Immunotherapy of Cancer

Article Title: Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy

doi: 10.1136/jitc-2025-012969

Figure Lengend Snippet: MCMV T cells are highly activated and cytotoxic within tumors. Immunophenotyping and cytokine production analysis of the TILs described in (25 days post-tumor implantation). (n=5/group). (A) Representative histograms of m45-specific CD8 T cells isolated from tumors (top) and MFI quantification (bottom). (B) Tumors were subjected to CD45+TIL magnetic separation and the purified cells were incubated with the six MCMV peptides for 4 hours, in the presence of GolgiPlug. The graphs show IFN-γ and TNF production in CD8 or CD4 Tconv cells. Results were compared by one-way ANOVA with Tukey correction. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ANOVA, analysis of variance; Gzm A and B, granzymes A and B; IFN, interferon; LAG3, lymphocyte activation gene 3 ; MCMV, murine cytomegalovirus; MFI, mean fluorescence intensity; Prf, perforin; PD-1, programmed cell death protein-1; Tconv, conventional T cell; TILs, tumor-infiltrating lymphocytes; TIM3, T cell immunoglobulin and mucin domain 3; TNF, tumor necrosis factor.

Article Snippet: When indicated, mice were intraperitoneally injected with anti-programmed cell death protein-1 (PD-1) (10 mg/kg two times a week, Bio X Cell, 29F.1A12), anti-Interleukin 10 Receptor (IL10R) (200 μg, once a week, Bio X Cell, 1B1.3A), anti-CD8 (200 μg, two times a week, Bio X Cell, YTS 169.4), anti-CD4 (100 μg two times a week, Bio X Cell, GK1.5) antibodies, or gemcitabine (5 mg/kg, two times a week, Selleck Chem).

Techniques: Tumor Implantation, Isolation, Purification, Incubation, Activation Assay, Fluorescence

Journal: Molecular Cancer

Article Title: Targeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy

doi: 10.1186/s12943-025-02529-x

Figure Lengend Snippet: SERPINB3 induces immunosuppression via upregulation of PD-L1 expression in tumor cells. A Heatmap showing classical common immune checkpoint ligand gene expression in ASPC-1-EV and ASPC-1-OE-SERPINB3 cells. B WB analysis of PD-L1 expression in the indicated ASPC-1 (EV or OE-SERPINB3) and BXPC-3 cells (NC or sh-SERPINB3). C-F mIFS and quantification of SERPINB3, PD-L1, and CD8 in clinical PDAC samples ( n = 43) and the results of correlation analysis. G Uniform manifold approximation and projection (UMAP) plot showing the expression of CD274 in cancer cells from the SERPINB3 hi and SERPINB3 low groups. H ASPC-1-EV and ASPC-1-OE-SERPINB3 cells were treated with or without trametinib (100 nM) for 48 h, and cell lysates were collected for WB analysis (left). Quantitative analysis of relative protein level of PD-L1 was shown (right). I-J Effects of anti-human PD-1 monoclonal antibodies (pembrolizumab biosimilar, Bio X Cell, 20 µg/ml) and trametinib (100 nM) on CD8 + T-cell-mediated cytotoxicity against the indicated ASPC-1 (EV or OE-SERPINB3) and BXPC-3 (NC or sh-SERPINB3) cells, as measured by lactate dehydrogenase (LDH) activity. K-L ELISA determination of interferon-γ (IFN-γ) ( J ) and granzyme B (GZMB) ( K ) levels in CD8 + T-cell cultures incubated for 24 h with medium from the indicated cells with or without anti-human PD-1 monoclonal antibodies (pembrolizumab biosimilar, Bio X Cell, 20 µg/ml). The indicated cells were pretreated with or without trametinib (100 nM) for 24 h. The levels of tumor-produced IFN-γ and GZMB were subtracted to determine the levels of T-cell-produced cytokines

Article Snippet: K-L ELISA determination of interferon-γ (IFN-γ) ( J ) and granzyme B (GZMB) ( K ) levels in CD8 + T-cell cultures incubated for 24 h with medium from the indicated cells with or without anti-human PD-1 monoclonal antibodies (pembrolizumab biosimilar, Bio X Cell, 20 μg/ml).

Techniques: Expressing, Gene Expression, Bioprocessing, Activity Assay, Enzyme-linked Immunosorbent Assay, Incubation, Produced

Journal: Molecular Cancer

Article Title: Targeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy

doi: 10.1186/s12943-025-02529-x

Figure Lengend Snippet: Induction of cuproptosis in combination with anti-PD-1 therapy can further inhibit the progression of SERPINB3 hi PDAC. A The workflow employed to establish C57BL/6 orthotopic tumor models and subsequent treatment. B-C Different groups of C57BL/6 mice received saline, anti-mouse PD-1 monoclonal antibodies (Bio X Cell, 100 µg, i.p., every three days), MOF-M-CuS x (200 µg/mL, 100 µL, via tail vein), or a combination of both for two weeks on day 14 following the orthotopic pancreatic injection of one million KPC-OE-SERPINB3 cells. Each mouse underwent in vivo bioluminescence imaging once a week from day 1 to day 28 postinjection, and the fluorescence intensities representing the tumor burden in each group were plotted individually ( B ). Representative bioluminescence images of the different groups on day 28 are presented ( C ). D-E Different groups of C57BL/6 mice received saline, anti-mouse PD-1 monoclonal antibodies (Bio X Cell, 100 µg, i.p., every three days), MOF-M-CuS x (200 µg/mL, 100 µL, via tail vein), or a combination of both for two weeks on day 14 following the orthotopic pancreatic injection of one million KPC-OE-SERPINB3 cells. Tumors were harvested at 4 weeks after pancreatic orthotopic injection ( D ), Bar chart showing the tumor volume from the mice in different groups ( E ). F-I Different groups of C57BL/6 mice received saline, anti-mouse PD-1 monoclonal antibodies (Bio X Cell, 100 µg, i.p., every three days), MOF-M-CuS x (200 µg/mL, 100 µL, via tail vein), or a combination of both for two weeks on day 14 following the orthotopic pancreatic injection of one million KPC-OE-SERPINB3 cells. Tumors were harvested at 4 weeks after pancreatic orthotopic injection for multiplex immunofluorescence staining ( G ) (white arrows indicate the representative CD8 + IFNγ + or CD8 + GZMB + cells). Bar charts showing the percentages of CD8 + T cells among all cells ( F ), IFNγ + cells among CD8 + T cells (H) and GZMB + cells among CD8 + T cells ( I ). J-L Different groups of C57BL/6 mice received saline, anti-mouse PD-1 monoclonal antibodies (Bio X Cell, 100 µg, i.p., every three days), MOF-M-CuS x (200 µg/mL, 100 µL, via tail vein), or a combination of both for two weeks on day 14 following the orthotopic pancreatic injection of one million KPC-OE-SERPINB3 cells. Tumors were harvested at 4 weeks after orthotopic pancreatic injection for flow cytometry analysis. Representative flow plots and bar charts showing the percentages of CD8 + T cells among CD45 + CD3 + cells ( J ), IFNγ + cells among CD8 + T cells ( K ) and GZMB + cells among CD8 + T cells ( L ). M Different groups of C57BL/6 mice received saline, anti-mouse PD-1 monoclonal antibodies (Bio X Cell, 100 µg, i.p., every three days), MOF-M-CuS x (200 µg/mL, 100 µL, via tail vein), or a combination of both beginning on day 14 following the orthotopic pancreatic injection of one million KPC-OE-SERPINB3 cells. Kaplan–Meier survival curves for each treatment group are presented

Article Snippet: K-L ELISA determination of interferon-γ (IFN-γ) ( J ) and granzyme B (GZMB) ( K ) levels in CD8 + T-cell cultures incubated for 24 h with medium from the indicated cells with or without anti-human PD-1 monoclonal antibodies (pembrolizumab biosimilar, Bio X Cell, 20 μg/ml).

Techniques: Saline, Bioprocessing, Injection, In Vivo, Imaging, Fluorescence, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry